156 results
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation
8-K
EX-10.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
related to the exercise of such warrants (“Other Warrant Exercise Agreement”), and no Holder shall be responsible in any way for the performance
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required
8-K
EX-4.2
rrelcm50uj6gkywcz
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
UPLOAD
vuoa28xwy
29 Jan 24
Letter from SEC
12:00am
8-K
EX-4.1
bz0tf6uzhtgz 6q4br22
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.2
f497leqi5x2 u4y
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
m2uaycd
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
4woxgy4qq0pgoacwczo6
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-10.1
a0y o8lko334
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.3
i2dnllm zef97cjilk
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm